共 8 条
[1]
Gulick R.M., Ribaudo H.J., Shikuma C.M., Et al., Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection, N. Engl. J. Med., 350, pp. 1850-1861, (2004)
[2]
Staszewski S., Morales-Ramirez J., Tashima K.T., Et al., Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults, N. Engl. J. Med., 341, pp. 1865-1873, (1999)
[3]
Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, (2005)
[4]
Nightingale S.L., From the food and drug administration, JAMA, 280, (1998)
[5]
Fundaro C., Genovese O., Rendeli C., Tamburrini E., Salvaggio E., Myelomeningocele in a child with intrauterine exposure to efavirenz, AIDS, 16, pp. 299-300, (2002)
[6]
De Santis M., Carducci B., De Santis L., Cavaliere A.F., Straface G., Periconceptional exposure to efavirenz and neural tube defects, Arch. Intern. Med., 162, (2002)
[7]
Antiretroviral Pregnancy Registry International Interim Report for January 1989 through 31 January 2004, (2004)
[8]
Botto L.D., Moore C.A., Khoury M.J., Erickson J.D., Neural-tube defects, N. Engl. J. Med., 341, pp. 1509-1609, (1999)